Caffein Consumption and Response Inhibition
Launched by UPPSALA UNIVERSITY · Mar 18, 2013
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
In a blinded, randomized cross-over design, participants will receive either a capsule with caffeine or placebo at two separate occasions whereupon study tasks will be performed.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Only males
- • 18 ≤ 35 years
- • Healthy (self rated)
- • Used to drink caffeine
- • Used to eat breakfast regularly (≥ 5 times a week).
- • Non-smokers
- Exclusion Criteria:
- • BMI outside the range of 18,5 ≤ 25
- • hypersensitivity for the ingredients of the foods under study
- • being a vegan or vegetarian. Participants reported not using products that are artificially sweetened, nor sugar in coffee and/or tea
- • Presence of any chronically disease and/or treatment with medication
About Uppsala University
Uppsala University, a prestigious institution located in Sweden, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive expertise in various fields of health sciences to conduct innovative studies aimed at improving patient outcomes and understanding complex diseases. With a strong emphasis on ethical standards and rigorous scientific methodologies, Uppsala University collaborates with a network of researchers, healthcare professionals, and industry partners to facilitate groundbreaking clinical trials that contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Uppsala, , Sweden
Patients applied
Trial Officials
Pleunie Hogenkamp, PhD
Principal Investigator
Uppsala University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials